ClinicalTrials.gg
RecruitingNCT07306247ALA-PDT-LSILUpdated Oct 16, 2026

Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection

An interventional study of ALA-PDT in HPV-16/18, Photodynamic Therapy (PDT) and LSIL, Low Grade Squamous Intraepithelial Lesion, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 5 sites in China. Open to female participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
20 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Squamous Intraepithelial Lesions with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Squamous Intraepithelial Lesions · China.

Planned enrollment
5th of 14
225 · median 153
Started
2026
with 3 others
No phase
7 of 26
6 open now
Primary completion
2027-01
later than 12 of 17 live
Registered
23rd of 26
by date
Lead sponsor
2 of 26
Second Affiliated Hospital, Zhejiang University, School of Medicine

Among the 26 studies in Squamous Intraepithelial Lesions with a site in China, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 23rd registered.

Squamous Intraepithelial Lesions

104 studies on the registry are indexed under Squamous Intraepithelial Lesions; 36 are open to participants now.

Browse Squamous Intraepithelial Lesions studies →

Open to participants now

17 of the 26 studies in Squamous Intraepithelial Lesions with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Squamous Intraepithelial Lesions studies recruiting now, 11 (48%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 20 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Squamous Intraepithelial Lesions with a site in China, or all of them as a file.
02

Study summary

This multicenter, prospective trial assesses ALA-PDT versus observation for efficacy and safety in treating cervical LSIL with HPV16/18 infection.

Read the detailed description

This study is a multicenter, prospective, concurrent, non-randomized controlled clinical trial designed to evaluate the clinical efficacy of ALA-PDT treatment compared with observation and follow-up in patients with cervical low-grade squamous intraepithelial lesion (LSIL) associated with HPV16/18 infection. The primary outcome is the cervical lesion reversal rate. Secondary outcomes include HPV16/18 clearance rate and time to clearance, as well as improvements in cervical ectropion and vaginal microenvironment. Additionally, lesion progression rate and recurrence rate will be monitored in both groups. Safety, tolerability, patient-reported quality of life, and treatment satisfaction are also assessed.

03

Conditions studied

  • HPV-16/18
  • Photodynamic Therapy (PDT)
  • LSIL, Low Grade Squamous Intraepithelial Lesion

Keywords

  • cervical low-grade squamous intraepithelial lesions
  • aminolevulinic acid-mediated photodynamic therapy
  • efficacy
  • human papillomavirus
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, 20-60 years, understands study procedures and consents to participate;
  2. HPV 16 or 18 positive;
  3. Colposcopy-guided cervical within 3 months showing LSIL;
  4. Provides written .

Exclusion criteria

Exclusion Criteria:

  1. Cytology showing ASC-H, HSIL, AGC, or AIS; or evidence of malignant cells on cytology/histology, or suspicion of or invasive cancer;
  2. Colposcopy findings suggestive of invasive cancer or lesion extension to the vaginal wall;
  3. Severe pelvic, cervical, or other gynecological inflammatory conditions identified clinically;
  4. Undiagnosed vaginal bleeding;
  5. Active allergic disease, porphyria, or history of allergy to the study drug or structurally similar agents;
  6. Severe cardiovascular, neurological, psychiatric, endocrine, hepatic, or hematologic disorders; known immunodeficiency; long-term or use; active disease; or other malignancies;
  7. Pregnant or breastfeeding women;
  8. History of hysterectomy, cervical cancer treatment, or cervical excision/ablation within 6 months (e.g., conization, LEEP, laser);
  9. Use of interferon or antiviral therapy within 3 months;
  10. Any other condition deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    ALA-PDT Group

    ALA-PDT administered every 7-14 days for a total of 3-6 sessions.

    Procedure: ALA-PDT

  • No intervention
    Observation Group

    Observation and follow-up

Interventions

  • ProcedureALA-PDT

    Photosensitizer is applied to the cervical canal and cervix, followed by light irradiation, repeated every 7-14 days for 3-6 sessions.

06

What researchers measure

Primary outcomes

  1. Cervical lesion regression rate

    Proportion of patients with normal histopathology on colposcopy-guided biopsy or NILM cytology, plus negative HPV test, at 6 months post-treatment.

    Time frame: 6 months

Secondary outcomes

  1. HPV clearance rate

    HPV clearance rates at 3, 6, 9, 12, and 24 months post-treatment

    Time frame: 2 years

  2. Cervical lesion regression rate

    Proportion of patients with normal colposcopy-guided cervical biopsy histopathology, or NILM cytology plus negative HPV test, at 12 and 24 months.

    Time frame: 2 years

Other outcomes

  1. Adverse events

    Record post-treatment bleeding, pain, and photosensitivity.

    Time frame: 2 years

07

Study locations

1 of 5 sites recruiting
08

References and documents

Publications

  • Li D, Wang Z, Liu Y, Zhou M, Xia B, Zhang L, Chen K, Zeng Y. Assessing the risk of high-grade squamous intraepithelial lesions (HSIL+) in women with LSIL biopsies: a machine learning-based study. Infect Agent Cancer. 2024 Dec 5;19(1):61. doi: 10.1186/s13027-024-00625-z. PubMed 39639322 ↗
  • Wang X, You L, Zhang W, Ma Y, Tang Y, Xu W. Evaluation of 5-aminolevulinic acid-mediated photodynamic therapy on cervical low-grade squamous intraepithelial lesions with high-risk HPV infection. Photodiagnosis Photodyn Ther. 2022 Jun;38:102807. doi: 10.1016/j.pdpdt.2022.102807. Epub 2022 Mar 11. PubMed 35288319 ↗
  • Qiu L, Li J, Chen F, Wang Y, Wang Y, Wang X, Lv Q, Li C, Li M, Yang Q, Wu D, Zhang Y, Zhang Y, Zhang M, Zhang Y, Qie M, Zhou H, Zhou J, Zhao W, Xia B, Liang X, Cai Y, Teng Y, Huang Z, Sui L, Wei L, Di W. Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). Photodiagnosis Photodyn Ther. 2022 Sep;39:102993. doi: 10.1016/j.pdpdt.2022.102993. Epub 2022 Jul 1. PubMed 35781093 ↗
  • Wang X, Xu X, Ma Y, Tang Y, Huang Z. Comparative Study of 5-Aminolevulinic Acid-Mediated Photodynamic Therapy and the Loop Electrosurgical Excision Procedure for the Treatment of Cervical High-Grade Squamous Intraepithelial Lesions. Pharmaceutics. 2024 May 20;16(5):686. doi: 10.3390/pharmaceutics16050686. PubMed 38794347 ↗
  • Persson M, Elfstrom KM, Olsson SE, Dillner J, Andersson S. Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. PLoS One. 2015 Jun 17;10(6):e0127444. doi: 10.1371/journal.pone.0127444. eCollection 2015. PubMed 26083247 ↗
  • Kusakabe M, Taguchi A, Sone K, Mori M, Osuga Y. Carcinogenesis and management of human papillomavirus-associated cervical cancer. Int J Clin Oncol. 2023 Aug;28(8):965-974. doi: 10.1007/s10147-023-02337-7. Epub 2023 Jun 9. PubMed 37294390 ↗
  • Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PubMed 38572751 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Dec 29, 2025
StartActual
Jan 21, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
Show 5 sites
  • Women's Hospital School Of Medicine Zhejiang University · Hangzhou, Chinano status→Recruiting
  • First People's Hospital of Hangzhou · Hangzhou, Chinano status→Not yet recruiting
  • Hangzhou Linping District first People's Hospital · Hangzhou, Chinano status→Not yet recruiting
  • First Affiliated Hospital of Ningbo University · Ningbo, Chinano status→Not yet recruiting
  • Shaoxing People's Hospital · Shaoxing, Chinano status→Not yet recruiting
Oct 16, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine; Collaborators removed: Linping First People's Hospital
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
    Show 5 sites
    • Women's Hospital School Of Medicine Zhejiang University · Hangzhou, Chinano status→Recruiting
    • First People's Hospital of Hangzhou · Hangzhou, Chinano status→Not yet recruiting
    • Hangzhou Linping District first People's Hospital · Hangzhou, Chinano status→Not yet recruiting
    • First Affiliated Hospital of Ningbo University · Ningbo, Chinano status→Not yet recruiting
    • Shaoxing People's Hospital · Shaoxing, Chinano status→Not yet recruiting
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine; Collaborators removed: Linping First People's Hospital
    + 3 other changes: identifiers, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07306247
Collaborators
Women's Hospital School Of Medicine Zhejiang University, First People's Hospital of Hangzhou, First Affiliated Hospital of Ningbo University, Shaoxing People's Hospital
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Jan 21, 2026
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Xiaoyun Wang, Doctor
Contact
doctorwangxy@zju.edu.cn
+86 0571-87783759
Jianwei Zhou, Professor
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion